Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer
- PMID: 20145176
- DOI: 10.1158/1078-0432.CCR-09-1643
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer
Abstract
Purpose: It has been suggested that a subgroup of human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with chromosome 17 (Chr-17) polysomy benefit from HER2-directed therapy. This hypothesis was examined using the data from a phase III trial that randomized patients with HER2-negative or HER2-untested metastatic breast cancer to first-line therapy with paclitaxel along with either lapatinib or placebo.
Experimental design: HER2 expression level by immunohistochemistry, fluorescence in situ hybridization (FISH), and mean HER2 ratio of Chr-17 values were determined centrally using archival tissue. Polysomy means of 2.0 and 2.2 served as thresholds.
Results: Of 580 patients on the original trial, 406 were HER2 negative by FISH. Progression-free survival (PFS) data were available for 405 patients, of whom 44 (11%) met the definition of polysomy (Chr-17 >or=2.2, FISH negative for HER2). Median PFS in the polysomy group was 20.9 and 24.4 weeks for paclitaxel plus lapatinib and paclitaxel plus placebo, respectively. In the nonpolysomy group, median PFS was 24.6 and 23.1 weeks for paclitaxel plus lapatinib and paclitaxel plus placebo, respectively. Log-rank testing showed no treatment advantage for either group. Similar results were found using a Chr-17 polysomy cutoff of 2.0. Response rates in the polysomy group were 17% for paclitaxel plus lapatinib and 10% for paclitaxel plus placebo. In the nonpolysomy group, response rates were 32% for paclitaxel plus lapatinib and 25% for paclitaxel plus placebo. Neither comparison was statistically significant.
Conclusion: This analysis could not confirm the hypothesis that Chr-17 polysomy in HER2-nonamplified patients improved chemotherapy outcome when lapatinib is added as a HER2-targeted treatment.
Comment in
-
Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter.Clin Cancer Res. 2010 Dec 15;16(24):6177; author reply 6178. doi: 10.1158/1078-0432.CCR-10-0773. Clin Cancer Res. 2010. PMID: 21169261 No abstract available.
Similar articles
-
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.J Clin Oncol. 2009 Nov 20;27(33):5552-8. doi: 10.1200/JCO.2008.21.1763. Epub 2009 Oct 26. J Clin Oncol. 2009. PMID: 19858400 Clinical Trial.
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28. J Clin Oncol. 2009. PMID: 19786658 Clinical Trial.
-
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.Curr Med Res Opin. 2010 Apr;26(4):767-75. doi: 10.1185/03007991003590860. Curr Med Res Opin. 2010. PMID: 20095796 Clinical Trial.
-
Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.Clin Ther. 2009;31 Pt 2:2332-48. doi: 10.1016/j.clinthera.2009.11.029. Clin Ther. 2009. PMID: 20110044 Review.
-
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Clin Ther. 2008. PMID: 18803986 Review.
Cited by
-
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?Int J Mol Sci. 2023 May 4;24(9):8206. doi: 10.3390/ijms24098206. Int J Mol Sci. 2023. PMID: 37175916 Free PMC article. Review.
-
Clinicopathological Features of Breast Cancer with Polysomy 17 and Its Response to Neoadjuvant Chemotherapy.Eur J Breast Health. 2021 Mar 31;17(2):128-136. doi: 10.4274/ejbh.galenos.2021.2021-2-9. eCollection 2021 Apr. Eur J Breast Health. 2021. PMID: 33870112 Free PMC article.
-
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.J Pathol Transl Med. 2020 Jan;54(1):34-44. doi: 10.4132/jptm.2019.11.03. Epub 2019 Nov 6. J Pathol Transl Med. 2020. PMID: 31693827 Free PMC article. Review.
-
HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study.Sci Rep. 2019 Aug 12;9(1):11679. doi: 10.1038/s41598-019-48212-2. Sci Rep. 2019. PMID: 31406196 Free PMC article.
-
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon.Oncotarget. 2016 Aug 23;7(34):54627-54631. doi: 10.18632/oncotarget.10559. Oncotarget. 2016. PMID: 27421137 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous